Famotidine Use in COVID-19

Read Article

To compare outcomes in patients hospitalized with Coronavirus (COVID-19), receiving famotidine therapy with those not receiving famotidine, a retrospective, propensity-matched observational study of consecutive COVID-19 positive patients was carried out between 2/24/2020 and 5/13/2020.

Of 878 patients in the analysis, 83 (9.5%), received famotidine. In comparison to patients not treated with famotidine, the patients treated with famotidine were younger (63.5 vs. 67.5 years), but did not differ with respect to baseline demographics or preexisting comorbidities. Use of famotidine was associated with a decreased risk of in-hospital mortality (OR 0.37), and combined death or intubation (OR 0.47). Propensity score matching to adjust for age difference between groups did not alter the effect on either outcome. In addition, patients receiving famotidine despite lower levels of serum markers for severe disease, including lower median peak CRP levels (9.4 vs. 12.7 mg/ dL), lower median procalcitonin levels (0.16 vs. 0.30 ng/mL), and a nonsignificant trend to lower median mean ferritin levels (797.5 vs. 964 ng/mL).

Logistic regression analysis demonstrated that famotidine was an independent predictor of both lower mortality and combined death/ intubation, whereas older age, BMI greater than 30 kg, chronic kidney disease, national early warning score, and higher neutrophil/ lymphocyte ratio were all predictors of adverse outcomes.

It was concluded that famotidine use in hospitalized patients with COVID-19 is associated with a lower risk of mortality, lower risk of combined outcome of mortality and intubation, and lower levels of serum markers for severe disease in hospitalized patients with COVID-19.

Mather, J., Seip, R., McKay, R. “Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.” American Journal of Gastroenterology 2020; Vol. 115, pp. 1617-1623.

Download Tables, Images & References